Drug Trial Radar · NCT04586335
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
24
Actual
Start
Sep 28, 2020
Primary completion
Feb 15, 2023
Study completion Feb 15, 2023
Sponsor
- Lead sponsor
- Haihe Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CYH33 in combination with olaprib in patients with DDR gene mutations and/or PIK3CA mutations, in patients who have progressed on prior PARP inhibitor, and in patients with recurrent high grade serous ovarian, fallopian tube, or primary peritoneal cancer who are platinum resistant or refractory. The study will assess if this combination will optimize anti-tumor activity, block tumor growth and overcome the resistance to PARP inhibitor treatment. The study consists 2 parts. In Part 1 dose escalation, the objective is to determine the maximum toleration dose (MTD) of the combination. The final recommended phase 2 dose (RP2D) of CYH33 in combination with olaparib will be based on the totality of an overall assessment of available safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy which could be the MTD or a dose level lower in specific cohorts of patients. In Part 2 dose expansion, the main objective is to evaluate the efficacy at RP2D.
Conditions
- Ovarian Cancer
- Breast Cancer
- Solid Tumor
- Prostate Cancer
- Endometrial Cancer
Interventions
CYH33Drug
Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLT)Time frame: 12 months
- Tumor objective response rate (ORR)Time frame: 38 months
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Yale Cancer Center
New Haven, Connecticut
UT Southwestern: Simmons Cancer Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Scientia Cancer Centre
Sydney, New South Wales, Australia
Integrated Oncology Network PTY LTD
Brisbane, Queensland, Australia
Monash Cancer Centre
Melbourne, Victoria, Australia
Fudan University - Pudong Medical Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.